Atossa Therapeutics, Inc. (ATOS): Operating Income
-$37.14M
Year ended 2025-12-31
-$39.25M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$37.14M | n/m | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | -$27.62M | n/m | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | -$31.38M | n/m | 2025-03-25, From 2023-01-01 |
| 2022-12-31 | -$27.69M | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$20.52M | n/m | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | -$14.61M | n/m | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | -$17.27M | n/m | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | -$11.43M | n/m | 2020-03-26, From 2018-01-01 |
| 2017-12-31 | -$7.65M | n/m | 2019-03-28, From 2017-01-01 |
| 2016-12-31 | -$7.97M | n/m | 2018-03-08, From 2016-01-01 |
| 2015-12-31 | -$12.76M | n/m | 2017-03-21, From 2015-01-01 |
| 2014-12-31 | -$12.17M | n/c | 2016-03-30, From 2014-01-01 |
| 2013-12-31 | -$10.78M | n/m | 2015-03-30, From 2013-01-01 |
| 2012-12-31 | -$5.07M | n/m | 2014-03-27, From 2012-01-01 |
| 2011-12-31 | -$3.43M | n/a | 2013-03-28, From 2011-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | -$37.14M | n/m |
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | -$17.27M | n/m |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | -$12.19M | n/m |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | -$72.13M | n/m |
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | -$29.52M | n/m |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | -$40.11M | n/m |
| Medicinova Inc (MNOV) | 2025-12-31 | -$13.28M | n/m |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | -$22.56M | n/m |
| NextCure, Inc. (NXTC) | 2025-12-31 | -$57.62M | n/m |
Compare ATOS, AKTX, VRCA, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗